OncLive TV

Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.

Whitney Goldsberry, MD, discusses considerations for selecting a PARP inhibitor in the maintenance treatment of ovarian cancer.

Jonathan Wesley Riess, MD, MS, discusses data from the phase 3 HARMONi-2 trial evaluating ivonescimab vs pembrolizumab in advanced NSCLC.

Yair Lotan, MD, discusses the evolving treatment paradigm for Bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer.

Laura A. Huppert, MD, discusses survival outcomes of patients with metastatic breast cancer and leptomeningeal disease according to disease subtype.

Polly Niravath, MD, discusses a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab in HER2-enriched early breast cancer.

Arvind N. Dasari, MD, MS, discusses the roles for the FDA-approved agents fruquintinib and TAS-102 plus bevacizumab in the mCRC treatment paradigm.

Charles E. Geyer, Jr., MD, discusses the efficacy and safety of perioperative atezolizumab plus chemotherapy in stage II/III triple-negative breast cancer.

Sattva S. Neelapu, MD, discusses a 5-year follow-up data for axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.

Rory Shallis, MD, discusses the addition of pembrolizumab to azacitidine citidine and venetoclax in patients with acute myeloid leukemia.

Dimitrios Nasioudis, MD, discusses preclinical study findings utilizing XPO1 inhibition for TP53 wild-type low-grade serous and clear cell ovarian cancer.

Patrick Borgen, MD, discusses how advances in artificial intelligence may influence the future of oncology practice.

Patrick I. Borgen, MD, discusses research outlining the current clinical applications and limitations of artificial intelligence in oncology practice.

Elizabeth Brem, MD, discusses data for odronextamab monotherapy in previously untreated patients with high-risk follicular lymphoma.

Daniel DeAngelo, MD, PhD, discusses the FDA approval of blinatumomab in the consolidation phase in CD19-positive, Ph-negative B-cell precursor ALL.

Daniel DeAngelo, MD, PhD, discusses the effect of avapritinib on bone density in patients with advanced systemic mastocytosis.

Sandip P. Patel, MD, discusses the potential role of antibody-drug conjugates in early-stage non–small cell lung cancer.

Pooja Phull, MD, discusses the use of ciltacabtagene autoleucel and idecabtagene vicleucel in R/R multiple myeloma.

Bhavana Bhatnagar, DO, discusses outcomes for allogeneic stem cell transplantation after blinatumomab plus chemotherapy in B-ALL.

Ashkan Emadi, MD, PhD, discusses responses achieved with venetoclax plus PegC in patients with venetoclax-pretreated, relapsed/refractory AML.

Alexis LeVee, MD, discusses immune-related adverse effects in patients with early breast cancer treated with immune checkpoint inhibitors.

Martin Dreyling, MD, discusses the role of autologous stem cell transplantation (ASCT) in the context of ibrutinib-containing first-line therapy for younger patients with MCL.

Tom van Meerten, MD, PhD, discusses the efficacy and safety of brexucabtagene autoleucel in BTK inhibitor–naive relapsed/refractory MCL.

John H. Strickler, MD, discusses the rationale for developing telisotuzumab adizutecan in MET gene–amplified advanced gastric cancer.

Junjie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

Peter Riedell, MD, discusses efficacy and safety of rapcabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Jorge Cortes, MD, discusses asciminib’s sustained efficacy and improved safety over other TKIs in first-line CML.

Michael R. Bishop, MD, discusses 34-month data from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory myeloma.

Meta: Lori A Leslie, MD, discusses 5-year follow-up data from the ZUMA-5 trial evaluating axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma.